AstraZeneca upgraded to Outperform from Market Perform at Leerink

theflyonthewall.com

Leerink upgraded AstraZeneca citing the company's evolution into a leader in biologics and specialty care. The firm raised its price target for shares to $68 from $55.

Rates

View Comments (0)